A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves mitochondrial function, improves myocardial energetics, and prevents degenerat ...

A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

This systematic review and network meta-analysis of 601 eligible trials found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1 receptor agonists were ...

The study offers promising news for people with type 2 diabetes. By using SGLT2 inhibitors, they may be able to lower their ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...